Medios AG has reported significant growth in its financial results for the first quarter of the year. The Berlin-based pharmaceutical company increased its adjusted EBITDA by 52.9% to €23.1 million, compared to €15.1 million in the same period last year. The group's net income after income taxes rose by 59.9% to €6.4 million, up from €4.0 million, partly due to the absence of one-off effects. Revenue increased by 6.2% to €484.7 million, compared to €466.2 million in the previous year's quarter. A substantial portion of the EBITDA growth is attributed to the expansion of the consolidation scope to include the Ceban Group, which contributed €7.2 million. Looking ahead, CEO Matthias Gärtner is optimistic, projecting an adjusted EBITDA margin of 4.8% for the current fiscal year, up from 3.4% in 2023 and 4.2% in 2024. The adjusted EBITDA is expected to rise by 21.5% to €96 million, with revenue anticipated to grow by approximately 6% to around €2 billion. This outlook assumes mid-single-digit organic growth and the consolidation of the Ceban Group for a full year. Despite these positive financial indicators, Medios AG's stock has been on a downward trend since the end of 2021, with the share price falling from over €40 in summer 2021 to €12.22 as of July 24, 2025. The stock has further decreased by 8.7% throughout the current year. CEO Gärtner has capitalized on the low valuations by repurchasing 1 million shares at €12.50 each, reflecting a belief among both the board and major shareholders that the stock is significantly undervalued.